2025 Clinical Trials Conditions 
Miss Marijuana
FEBRUARY 7, 2025
As of 2025 , the legal status of THC and CBD is still evolving. Whether you’re dealing with a sports injury or chronic pain conditions, CBD might offer some relief. CBD has been found to have anti-inflammatory effects , which can help with conditions like arthritis, muscle soreness, and even more serious inflammatory diseases.
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 23, 2021
billion by 2025. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage.
Miss Marijuana
FEBRUARY 1, 2025
Clinical trials are currently underway, so keep an eye out for new findings. They don’t get you high, but they can work wonders for relieving pain, inflammation, or even skin conditions. Some states have fully legal medical cannabis programs, while others may only allow CBD products or restrict usage to certain conditions.
Cannabis Law Report
FEBRUARY 9, 2022
There’s also concern about a rare condition known as wood lover’s paralysis , a condition that produces muscle weakness a few hours after hallucinogenic mushrooms are consumed. Scientists don’t know why this condition occurs, but it isn’t believed to happen with Psilocybe cubensis. Other species might be introduced later.
Puff Puff Post
DECEMBER 28, 2018
They aren’t geared towards treating the condition specifically, and rather focus on reducing side-effects from the disorder like anxiety and insomnia. This is on par with the cost currently seen for those afflicted with ADHD and diabetes, with predictions for the cost to skyrocket further by 2025.
Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6.
Expert insights. Personalized for you.
52 
Let's personalize your content